Targets › COX1
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout May 2027.
Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the…. (UniProt, P23219)
Open in Phaseline: the race on COX1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Avidence Therapeutics | AVD275 Intra-articular Injection Cyclooxygenase (COX) inhibitor | COX1, COX2 | Phase 1 | Osteoarthritis of the Knee | May 2027 |
Osteoarthritis of the Knee (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.